We are live on ! Find out more
DGM

Darwin Global Management Portfolio holdings

AUM $3.77B
1-Year Est. Return 307.72%
This Fund
S&P 500
This Quarter Est. Return
+91.94%
1 Year Est. Return
+307.72%
3 Year Est. Return
+2,873.14%
5 Year Est. Return
+48,315.58%
10 Year Est. Return
–
AUM
$366M
AUM Growth
+$205M
Cap. Flow
+$143M
Cap. Flow %
39.03%
Top 10 Hldgs %
100%
Holding
5
New
1
Increased
1
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
TGTX icon
TG Therapeutics
TGTX
+$159M
2
AMAM
Ambrx Biopharma Inc
AMAM
+$18.7M

Top Sells

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$20.1M
2
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$10.1M
3
ARGX icon
argenx
ARGX
+$4.63M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TGTX icon
1
TG Therapeutics
TGTX
$8.4B
$157M 42.99%
+10,451,241
New +$159M
ARGX icon
2
argenx
ARGX
$53.8B
$106M 29.06%
285,198
-12,503
-4% -$4.63M
AMAM
3
DELISTED
Ambrx Biopharma Inc
AMAM
$101M 27.58%
11,304,573
+3,720,084
+49% +$18.7M
KROS icon
4
Keros Therapeutics
KROS
$211M
$1.34M 0.37%
31,386
-397,146
-93% -$20.1M
RXDX
5
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
– –
-91,379
Closed -$10.1M

Similar funds

VVP
Vulcan Value Partners Birmingham, Alabama $3.77B AUM 9.63% 1-Year Est. Return
ABC
Associated Banc-Corp Green Bay, Wisconsin $3.78B AUM 21.74% 1-Year Est. Return
SCA
Snowden Capital Advisors New York $3.76B AUM 23.4% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
VA
VestGen Advisors Inverness, Illinois $3.76B AUM 26.04% 1-Year Est. Return
GCC
Guardian Capital (Canada) Toronto, Ontario, Canada $3.78B AUM 33.04% 1-Year Est. Return
SB
SIG Brokerage New York $3.79B AUM 44.46% 1-Year Est. Return

Darwin Global Management's Q1 2023 Portfolio in Review

As of Q1 2023, Darwin Global Management held 5 positions worth $366M, up 128% from $161M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Darwin Global Management deployed $143M of net new capital in Q1 2023, opening 1 new position and adding to 1 existing holding. Its largest new stake was TG Therapeutics: 10,451,241 shares worth $157M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Keros Therapeutics, an estimated $20.1M trimmed.

  • Darwin Global Management's largest Q1 2023 buy was TG Therapeutics: 10,451,241 shares worth $157M.
  • Darwin Global Management added most to Ambrx Biopharma Inc in Q1 2023, an estimated $18.7M increase.
  • Darwin Global Management's biggest Q1 2023 reduction was Keros Therapeutics, cutting an estimated $20.1M.
  • Darwin Global Management fully exited Prometheus Biosciences, Inc. Common Stock in Q1 2023, selling an estimated $10.1M.
  • Darwin Global Management's ten largest holdings make up 100% of its $366M portfolio in Q1 2023.
  • Darwin Global Management opened 1 new position and closed 1 in Q1 2023.
  • Darwin Global Management's portfolio value rose 128% quarter-over-quarter to $366M.

Based on Darwin Global Management's 13F filing for Q1 2023, filed 15 May 2023.